Monitor for any future conversion to Schedule 13D, which would signal an activist intent. The passive stake remains unchanged, so no immediate trading catalyst.
IMTX drugs
IMTX drug pipeline →Price Chart
How similar events traded
Executive Summary
Montanova Capital, LLC filed Amendment No. 4 to its Schedule 13G, reporting beneficial ownership of 8,750,816 ordinary shares (5.8%) of Immatics N.V. as of September 30, 2026. The filing is a routine passive stake update with no change in ownership percentage from the prior filing, indicating the stake was maintained.
Key Financial Metrics
Key Facts
- Montanova Capital, LLC reported 8,750,816 ordinary shares (5.8% of class) as of September 30, 2026.
- Averill Master Fund, Ltd. holds 7,464,908 shares (4.99%) as part of the same group.
- Aaron Cowen is the control person of Montanova Capital, LLC.
- This is Amendment No. 4 to the Schedule 13G, filed under Rule 13d-1(b) as a passive investor.
- The filing certifies the securities were not acquired to change or influence control of the issuer.
Financial Impact
No material financial impact; stake value approximately $58 million based on $1.0B market cap and 5.8% ownership.
Risk Factors
- No material risks identified from this routine passive stake update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000919574-26-007762 |
| Document: p15120077_exh-b.htm | 0000919574-26-007762 |
| Document: 0000919574-26-007762-index-headers.html | 0000919574-26-007762 |
| Document: 0000919574-26-007762-index.html | 0000919574-26-007762 |
| Document: 0000919574-26-007762.txt | 0000919574-26-007762 |
Track record
23 reports on IMTX
8 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers